Compare RBC & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBC | INCY |
|---|---|---|
| Founded | 1919 | 1991 |
| Country | United States | United States |
| Employees | 5334 | N/A |
| Industry | Metal Fabrications | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 17.0B |
| IPO Year | N/A | 1994 |
| Metric | RBC | INCY |
|---|---|---|
| Price | $581.00 | $97.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 21 |
| Target Price | ★ $510.00 | $103.52 |
| AVG Volume (30 Days) | 219.8K | ★ 1.2M |
| Earning Date | 05-15-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | N/A | ★ 1.47 |
| Revenue | N/A | ★ $3,394,635,000.00 |
| Revenue This Year | $15.20 | $10.44 |
| Revenue Next Year | $12.36 | $10.99 |
| P/E Ratio | ★ $64.90 | $66.16 |
| Revenue Growth | N/A | ★ 13.67 |
| 52 Week Low | $355.47 | $63.93 |
| 52 Week High | $632.00 | $112.29 |
| Indicator | RBC | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 49.45 | 51.42 |
| Support Level | $574.08 | $93.17 |
| Resistance Level | $598.31 | $103.11 |
| Average True Range (ATR) | 19.89 | 2.45 |
| MACD | -4.87 | -0.15 |
| Stochastic Oscillator | 42.77 | 37.04 |
RBC Bearings is an international manufacturer and marketer of engineered precision bearings, components, and essential systems for the industrial, defense, and aerospace industries. The offering includes plain bearings, roller bearings, ball bearings, and engineered products. The company has two reportable segments: industrial, which generates the most revenue, and aerospace and defense. The A&D segment represents the end markets for the company's engineered bearings and precision components used in commercial aerospace, defense aerospace, and sea and ground defense applications; and the industrial segment represents the end markets for its products used in various industrial applications. Geographically, the company generates a majority of its revenue from the United States.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.